Novartis AG
SIX:NOVN
Intrinsic Value
Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. [ Read More ]
The intrinsic value of one NOVN stock under the Base Case scenario is 86.09 CHF. Compared to the current market price of 89.53 CHF, Novartis AG is Overvalued by 4%.
Valuation Backtest
Novartis AG
Run backtest to discover the historical profit from buying and selling NOVN stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Novartis AG
Current Assets | 30.5B |
Cash & Short-Term Investments | 14.1B |
Receivables | 7.5B |
Other Current Assets | 8.9B |
Non-Current Assets | 69.5B |
Long-Term Investments | 2.8B |
PP&E | 10.9B |
Intangibles | 50.2B |
Other Non-Current Assets | 5.5B |
Current Liabilities | 26.4B |
Accounts Payable | 4.9B |
Other Current Liabilities | 21.5B |
Non-Current Liabilities | 26.9B |
Long-Term Debt | 20B |
Other Non-Current Liabilities | 6.9B |
Earnings Waterfall
Novartis AG
Revenue
|
46.7B
USD
|
Cost of Revenue
|
-12B
USD
|
Gross Profit
|
34.6B
USD
|
Operating Expenses
|
-22B
USD
|
Operating Income
|
12.6B
USD
|
Other Expenses
|
2.2B
USD
|
Net Income
|
14.9B
USD
|
Free Cash Flow Analysis
Novartis AG
NOVN Profitability Score
Profitability Due Diligence
Novartis AG's profitability score is 67/100. The higher the profitability score, the more profitable the company is.
Score
Novartis AG's profitability score is 67/100. The higher the profitability score, the more profitable the company is.
NOVN Solvency Score
Solvency Due Diligence
Novartis AG's solvency score is 68/100. The higher the solvency score, the more solvent the company is.
Score
Novartis AG's solvency score is 68/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
NOVN Price Targets Summary
Novartis AG
According to Wall Street analysts, the average 1-year price target for NOVN is 98.17 CHF with a low forecast of 74.74 CHF and a high forecast of 115.5 CHF.
Shareholder Return
NOVN Price
Novartis AG
Average Annual Return | 4.22% |
Standard Deviation of Annual Returns | 8.89% |
Max Drawdown | -24% |
Market Capitalization | 182.8B CHF |
Shares Outstanding | 2 044 029 952 |
Percentage of Shares Shorted |
N/A
|
NOVN News
Last Important Events
Novartis AG
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Novartis AG
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. The company is headquartered in Basel, Basel-Stadt and currently employs 104,323 full-time employees. The company went IPO on 2001-05-07. The firm develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The firm uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.
Contact
IPO
Employees
Officers
The intrinsic value of one NOVN stock under the Base Case scenario is 86.09 CHF.
Compared to the current market price of 89.53 CHF, Novartis AG is Overvalued by 4%.